Alkermes Rises 3% Ahead Of Earnings (ALKS)

Shares of biotechnology firm Alkermes ALKS are rising on heavy volume ahead of the company's quarterly earnings report which is due out after the closing bell. Analysts have consensus EPS estimates calling for a loss of $0.14, which compares to a loss of $0.15 in the year ago period. Revenues are anticipated to be $46.32 million versus $38.48 million in last year's corresponding quarter. During Thursday's trading session, ALKS shares have added 3.17% to $16.91. More than 1.5 million ALKS shares have traded hands compared to a daily average of around 700,000. Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder.